Avila bags $40 million up front in oncology drug pact with Sanofi-Aventis
This article was originally published in Scrip
Avila Therapeutics is to develop drugs that bind covalently to their targets with Sanofi-Aventis for cancer treatment. The companies will design targeted covalent drugs directed towards six undisclosed tumour signalling proteins. Avila is to receive $40 million in up-front and research support payments and is eligible for milestone payments of up to $154 million for each of the six programmes up to regulatory approval.